Last reviewed · How we verify
CGRP infusion
At a glance
| Generic name | CGRP infusion |
|---|---|
| Sponsor | Danish Headache Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications (PHASE4)
- Treatment of Atypical Resistant Facial Pain
- Facilitators and Barriers to Eptinezumab Administration in Thailand
- Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide (NA)
- A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy (PHASE2)
- Real World Effectiveness of Eptinezumab in Participants With Migraine (PHASE4)
- Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients. (NA)
- Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CGRP infusion CI brief — competitive landscape report
- CGRP infusion updates RSS · CI watch RSS
- Danish Headache Center portfolio CI